Trixeo Aerosphere ( formoterol / glycopyrronium / budesonide)
Indication
a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist.
Restriction: Triple therapy should be reserved for patients who have failed to achieve or maintain an adequate response to an appropriate course of dual therapy.
Green (Restricted)
Brand:
Trixeo Aerosphere
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Respiratory system
Background
Recommendation
LSCMMG Recommendation:
Green (Restricted)
Reason for decision:
Suitable for initiation in primary care in line with restrictions
Supporting documents: